Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 16/20 | 0.75 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.75 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048253 | 1.00 | SLC5A2 (0.75) | SLC5A2SLC5A1CHRM5CHRM1CHRM2 | |
| SCHEMBL13110356 | 0.86 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL3046189 | 0.83 | SLC5A2 (0.75) | SLC5A2SLC5A1 | |
| SCHEMBL3052408 | 0.82 | SLC5A2 (0.73) | SLC5A2SLC5A1CHRM5CHRM1CHRM2 | |
| SCHEMBL3048257 | 0.82 | SLC5A2 (0.73) | SLC5A2SLC5A1CHRM5CHRM1CHRM2 | |
| SCHEMBL3048254 | 0.82 | SLC5A2 (0.73) | SLC5A2SLC5A1CHRM5CHRM1CHRM2 | |
| SCHEMBL3405159 | 0.78 | SLC5A2 (0.76) | SLC5A2SLC5A1CHRM5CHRM1CHRM2 | |
| SCHEMBL3045020 | 0.78 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL3428662 | 0.77 | SLC5A2 (0.75) | SLC5A2SLC5A1CHRM5CHRM1CHRM2 | |
| SCHEMBL3412682 | 0.77 | SLC5A2 (0.56) | SLC5A2SLC5A1CHRM5CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820630-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-26 | — | — | US | disclosed |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | SLC5A2 10/4885SLC5A1 14/4885CHRM5 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.